Circassia Pharmaceuticals plc will focus on its respiratory business following disappointing top-line results from its phase IIb house dust mite allergy immunotherapy study announced today.
As with last year’s phase III cat allergy trial, in the study both the active treatment and placebo greatly reduced subjects’ allergy symptoms and rescue medication use. As the treatment did not show a significant effect compared with placebo, the study did not meet its primary endpoint.. Following these results, Circassia will make no further investment in its allergy programmes.
The Company will now focus on its respiratory business, with its broad portfolio of marketed and development products offering significant commercial potential. Circassia plans to continue the growth of its market-leading NIOX® asthma management franchise, accelerating its newly established US commercial collaboration with AstraZeneca for Tudorza® and Duaklir®, leveraging its specialty commercial infrastructure as a strategic growth platform and progressing the development of its respiratory pipeline.
Steve Harris, Circassia’s Chief Executive, said:
“We are naturally disappointed by this outcome, which is in line with our cat allergy phase III study where there was also a very marked placebo effect. Although subjects receiving the immunotherapies in both these studies had greatly improved allergy symptoms, the strong placebo effect made it highly challenging to achieve the studies’ endpoints.”